文献速递中医妇科中药与中成药合理使用

逍遥散治疗多囊卵巢综合征的系统评价与Meta分析

Efficacy and safety of Chinese patent medicine Xiao Yao San in polycystic ovary syndrome: A systematic review and meta-analysis.
PubMed 文献 · J Ethnopharmacol · 2023-04-25

该系统评价与Meta分析纳入9项RCT共736例多囊卵巢综合征患者,检索7个数据库至2022年7月。结果显示逍遥散联合常规西药可显著提高排卵率(OR=2.45)和妊娠率(OR=2.65),并降低空腹胰岛素(SMD=-0.46)和HOMA-IR(SMD=-0.65),但对总睾酮、FSH、LH和空腹血糖无显著影响,未见严重不良反应。

要点

  • 逍遥散联合常规西药可提高PCOS患者排卵率和妊娠率。
  • 逍遥散联合常规西药可降低空腹胰岛素和HOMA-IR水平。
  • 对总睾酮、FSH、LH和空腹血糖无显著影响,未见严重不良反应。

核心结论

  • 逍遥散联合常规西药可改善PCOS患者排卵率、妊娠率,并降低FINS和HOMA-IR,可能作为常规西药的有前景的辅助治疗。
  • 因存在显著异质性和方法学缺陷,结果需谨慎解读,仍需更大规模、更高质量的RCT严格评估。

研究设计与样本

  • 系统评价与Meta分析,检索7个数据库(Cochrane Library、PubMed、Embase、万方、中国生物医学文献数据库、CNKI、维普)从建库至2022年7月的RCT。
  • 共纳入9项试验,包括736例PCOS患者。
  • 采用随机效应模型或固定效应模型合并数据,效应量以OR或SMD及95%CI报告。

主要发现

  • 逍遥散联合常规西药显著提高排卵率(OR=2.45,95%CI=1.94至3.08,P<0.001)。
  • 逍遥散联合常规西药显著提高妊娠率(OR=2.65,95%CI=1.87至3.75,P<0.001)。
  • 逍遥散联合常规西药降低空腹胰岛素(FINS)水平(SMD=-0.46,95%CI=0.65至-0.27,P<0.001)。
  • 逍遥散联合常规西药降低HOMA-IR(SMD=-0.65,95%CI=-0.93至-0.37,P<0.001)。
  • 对总睾酮(T)、FSH、LH和空腹血糖(FPG)水平无显著影响,未见严重不良反应。

临床怎么用

  • 在常规西药治疗PCOS基础上,可考虑联合逍遥散以改善排卵和妊娠结局,并改善胰岛素抵抗指标。
  • 使用时应关注总睾酮、FSH、LH和空腹血糖无显著改善的证据,不将其作为这些指标的替代治疗。

局限性

  • 纳入研究存在显著异质性。
  • 纳入研究存在方法学缺陷。
  • 结果需谨慎解读,仍需更大规模、更高质量的RCT严格评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGICAL RELEVANCE: Polycystic ovary syndrome (PCOS) is one of the most common endocrine-metabolic disorders in women of reproductive age worldwide. Previous studies using randomized controlled trials (RCTs) have revealed that Xiao Yao San (XYS), a classic Chinese patent medicine formula, can effectively treat PCOS. However, the entire evidence has yet to be systematically summarized. AIM OF THE STUDY: The aim of this systematic review and meta-analysis of clinical trials was to assess the effect of XYS for the treatment of PCOS. MATERIALS AND METHODS: 7 databases were thoroughly reviewed for RCTs published from inception to July 2022, assessing the effect of XYS in treating PCOS, including Cochrane Library, PubMed, Embase, Wan Fang Database, Chinese Biomedical Database, China National Knowledge Infrastructure, and China Science and Technology Journal Database. Outcome measures included ovulation rate, pregnancy rate, hormonal levels, and glycemic parameters. Either a random-effects model or a fixed-effect models was used to pool data. Pooled effect sizes were reported as odds ratios (ORs) or standardized mean differences (SMDs) with their 95% confidence intervals (CIs). RESULTS: A total of 9 trials including 736 PCOS patients met the selection criteria. Our results indicate that XYS plus conventional medicines for PCOS significantly improved ovulation rate (OR = 2.45, 95% CI = 1.94 to 3.08, P < 0.001) and pregnancy rate (OR = 2.65, 95% CI = 1.87 to 3.75, P < 0.001), meanwhile decreased levels of fasting insulin (FINS) (SMD = - 0.46, 95% CI: 0.65 to - 0.27, P < 0.001) and homeostatic model assessment for insulin resistance (HOMA-IR) (SMD = - 0.65, 95% CI = - 0.93 to - 0.37, P < 0.001). XYS plus conventional medicines for PCOS did not have a significant impact on levels of total testosterone (T), follicle-stimulating hormone (FSH), luteinizing hormone (LH), and fasting plasma glucose (FPG). No serious adverse reactions were observed. CONCLUSION: XYS combined with conventional medicines can improve ovulation and pregnancy rates, decrease FINS and HOMA-IR in PCOS patients, indicating that XYS treatment may be used as a promising adjuvant therapy to the conventional medicines of PCOS. However, due to significant heterogeneity and methodological shortcomings, these results should be interpreted with great caution. Larger, higher quality RCTs are needed to rigorously assess the effect of XYS as a complementary therapy in managing PCOS.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. Zhou X, Ma Q, Yan Z, et al. Efficacy and safety of Chinese patent medicine Xiao Yao San in polycystic ovary syndrome: A systematic review and meta-analysis. J Ethnopharmacol. 2023. PMID: 37105369. doi:10.1016/j.jep.2023.116517

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。